← All trials
NCT04639869
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2019
- Primary completion
- Jul 26, 2019
- Completion date
- Aug 27, 2019
- First posted
- Nov 23, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 44
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.Lead sponsor
- Farmagen Ar-Ge Biyot. Ltd. StiOverall official - principal investigator
- Farmagen Ar-Ge Biyot. Ltd. StiStudy chair
- Farmagen Ar-Ge Biyot. Ltd. StiCollaborator
- Novagenix Bioanalytical Drug R&D CenterCollaborator
- Pharmactive İlaç San.ve Tic.A.SStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.